2001
Development and Characterization of a Molecular Viability Assay for Pneumocystis carinii f sp hominis
Maher N, Vermund S, Welsh D, Dillon H, Awooda A, Unnasch T. Development and Characterization of a Molecular Viability Assay for Pneumocystis carinii f sp hominis. The Journal Of Infectious Diseases 2001, 183: 1825-1827. PMID: 11372040, DOI: 10.1086/320738.Peer-Reviewed Original ResearchConceptsPneumocystis carinii pneumoniaHuman immunodeficiency virus-infected personsP. cariniiCommon opportunistic infectionVirus-infected personsCarinii pneumoniaOpportunistic infectionsPerson transmissionHuman P. cariniiClinical specimensTransmission dynamicsCariniiInfectionViability assaysMolecular viabilityImportance of personPneumoniaReliable methodEpidemiologyPersons
2000
Development and Evaluation of a Molecular Viability Assay for Pneumocystis carinii
Maher N, Vermund S, Lasbury M, Lee C, Bartlett M, Unnasch T. Development and Evaluation of a Molecular Viability Assay for Pneumocystis carinii. Journal Of Clinical Microbiology 2000, 38: 1947-1952. PMID: 10790126, PMCID: PMC86630, DOI: 10.1128/jcm.38.5.1947-1952.2000.Peer-Reviewed Original ResearchConceptsPneumocystis carinii pneumoniaRespiratory specimensP. cariniiViable trophozoitesPatient respiratory specimensP. carinii DNAOpportunistic illnessesViability assaysCarinii pneumoniaPCP patientsShock protein 70 familyReverse transcription-PCRHeat shock protein 70 familyPneumocystis cariniiNoninvasive techniqueCarinii DNACariniiTranscription-PCREthidium bromide stainingOptimal assay conditionsTrophozoitesBromide stainingAssaysMolecular viabilitySpecific primers
1994
Incidence Of Clinical Aids Conditions In A Cohort Of Homosexual Men With CD4+ Cell Counts <100/mm3
Bacellar H, Muñoz A, Hoover D, Phair J, Besley D, Kingsley L, Vermund S, Study F. Incidence Of Clinical Aids Conditions In A Cohort Of Homosexual Men With CD4+ Cell Counts <100/mm3. The Journal Of Infectious Diseases 1994, 170: 1284-1287. PMID: 7963728, DOI: 10.1093/infdis/170.5.1284.Peer-Reviewed Original ResearchConceptsIncidence rateHomosexual menCD4 cells/mm3P. carinii pneumonia prophylaxisHuman immunodeficiency virus type 1Multicenter AIDS Cohort StudyImmunodeficiency virus type 1Cells/mm3Use of antiretroviralsPneumocystis carinii pneumoniaAIDS Cohort StudyHealth care providersMycobacterium avium complexVirus type 1Cytomegalovirus diseasePneumonia prophylaxisCytomegalovirus retinitisAIDS illnessCohort studyOpportunistic infectionsAIDS conditionsCarinii pneumoniaClinical trialsKaposi's sarcomaCare providers
1993
Trends in the Incidence of Outcomes Defining Acquired Immunodeficiency Syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985–1991
Muñoz A, Schrager L, Bacellar H, Speizer I, Vermund S, Detels R, Saah A, Kingsley L, Seminara D, Phair J. Trends in the Incidence of Outcomes Defining Acquired Immunodeficiency Syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985–1991. American Journal Of Epidemiology 1993, 137: 423-438. PMID: 8096356, DOI: 10.1093/oxfordjournals.aje.a116691.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic InfectionsCD4-Positive T-LymphocytesCohort StudiesCytomegalovirus InfectionsHerpes SimplexHIV SeropositivityHIV-1HumansIncidenceLeukocyte CountLymphomaMaleNervous System DiseasesPneumonia, PneumocystisProspective StudiesRegression AnalysisRisk FactorsSarcoma, KaposiUnited StatesConceptsAcquired Immunodeficiency SyndromeP. carinii pneumoniaCarinii pneumoniaProgressive immunosuppressionKaposi's sarcomaImmunodeficiency syndromeOpportunistic infectionsHerpes simplex virus infectionHuman immunodeficiency virus type 1Multicenter AIDS Cohort StudyImmunodeficiency virus type 1Use of chemoprophylaxisUse of prophylaxisIncidence of outcomesPneumocystis carinii pneumoniaSimplex virus infectionAIDS Cohort StudyVirus type 1Antiretroviral therapyCohort studyClinical outcomesInitial diagnosisSecondary diagnosisLower incidenceNeurologic disease
1992
The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection
Graham N, Zeger S, Park L, Vermund S, Detels R, Rinaldo C, Phair J. The Effects on Survival of Early Treatment of Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1992, 326: 1037-1042. PMID: 1347907, DOI: 10.1056/nejm199204163261601.Peer-Reviewed Original ResearchMeSH KeywordsCD4-Positive T-LymphocytesCohort StudiesFollow-Up StudiesHIV InfectionsHumansLeukocyte CountMalePneumonia, PneumocystisTime FactorsZidovudineConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDevelopment of AIDSPneumocystis carinii pneumoniaPCP prophylaxisProlong survivalEarly treatmentRelative riskVirus infectionCell countUse of zidovudineUse of prophylaxisDiagnosis of AIDSHIV Type 1HIV-1 infectionBasis of CD4High-risk menInitial disease stateProbability of deathZidovudine usersZidovudine therapyImmunodeficiency syndromeCarinii pneumoniaClinical symptomsProphylaxis
1991
Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS
STUDY T, Graham N, Zeger S, Park L, Saah A, Phair J, Detels R, Vermund S, Ho M. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Lancet 1991, 338: 265-269. PMID: 1677108, DOI: 10.1016/0140-6736(91)90414-k.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAerosolsCD4-Positive T-LymphocytesEvaluation Studies as TopicFollow-Up StudiesHIV SeropositivityHIV-1HumansLeukocyte CountMalePentamidinePneumonia, PneumocystisProspective StudiesRegression AnalysisRisk FactorsTime FactorsTrimethoprim, Sulfamethoxazole Drug CombinationZidovudineConceptsPneumocystis carinii pneumoniaEffect of zidovudineHIV-1 infectionPCP prophylaxisProbability of progressionLymphocytes/First episodePneumocystis carinii pneumonia prophylaxisHIV-1-infected individualsHIV-1-seropositive menMonth intervalsPrimary PCP prophylaxisEfficacy of zidovudinePresence of HIVRate of progressionMultivariate log-linear modelPneumonia prophylaxisMore CD4Primary prophylaxisZidovudine therapyLymphocyte countCarinii pneumoniaClinical trialsObservational studyProphylaxis
1990
How can epidemiology assist in guiding interventions for the acquired immunodeficiency syndrome/human immunodeficiency virus?
Vermund S, Hoth D. How can epidemiology assist in guiding interventions for the acquired immunodeficiency syndrome/human immunodeficiency virus? Annals Of Epidemiology 1990, 1: 141-155. PMID: 1669495, DOI: 10.1016/1047-2797(90)90005-d.Peer-Reviewed Original ResearchConceptsNew therapiesHIV infectionTherapeutic trialsClinical trialsImmunodeficiency syndrome/human immunodeficiency virusVaccine developmentHuman immunodeficiency virus (HIV) infectionRecent drug trialsImmunodeficiency virus infectionDevelopment of AIDSHost immunologic responseHuman immunodeficiency virusSuch clinical parametersFuture epidemiologic researchClinical therapeutic researchNatural history studiesUse of condomsEffect of treatmentClinical research methodsVariety of treatmentsAIDS/HIV epidemicClinical courseClinical outcomesClinical parametersImmunodeficiency virus